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Abstract
Introduction. The correlation between the premenopausal estrogen hormone and estrogen receptors is unknown. The hormone estrogen has a risk factor for causing
breast cancer. Meanwhile, the estrogen receptor plays a role in determining further treatment plans in breast cancer patients. Patients with high estrogen receptors have a
better prognosis. If the premenopausal estrogen hormone can affect the estrogen-receptor, then the estrogen hormone can be modified to have a better prognosis.
Method. A cross-sectional study enrolled 32 subjects with complete data and was statistically analyzed to find the correlation between premenopausal estrogen hormone
and estrogen-receptors.
Results. The estradiol ranged from 15.3 − 89.8 pg/mL, and estrogen receptors showed a range of 10–90%. The Spearman correlation test between the estradiol and the
estrogen receptor showed a p-value = 0.864 and a negative correlation coefficient of 0.032.
Conclusion. Estrogen hormone is not statistically associated with estrogen receptors in premenopausal breast cancer patients, thus illustrating that the prognosis of breast
cancer is not associated with the estrogen hormone.
Keywords: breast cancer; estradiol; estrogens; estrogen-receptors; premenopausal hormones

Introduction
Method
Hormonal factors rolled as a risk factor in breast cancer, in addition to
other carcinogenic factors such as chemicals, irradiation, viruses,
genetics, and chronic irritation, as well as behavioral/lifestyle factors
such as smoking, unhealthy eating patterns, alcohol consumption, and
lack of physical activity.1-3 Of the hormonal factor, estrogen is the crucial
one. Estrogen is divided into endogenous and exogenous estrogens. The
endogenous is found in three potential forms: estradiol, estrone, and
estriol. Both exogenous and endogenous estrogen is referred to as the
risk factors for breast cancer.3
Estrogen receptors showed a clinically important, that is, planning
further treatment. High estrogen receptors reflect a good response to
hormone therapy. In addition, high estrogen receptors have a better
prognosis than those with low or no receptors. The correlation between
estrogen and the estrogen receptor has been studied previously and
showed contradictory findings. Some studies showed a significant
correlation between estrogen and the estrogen–receptor, 4,5 particularly
in the luteal phase and the positive estrogen receptor. However, another
study showed that estrogen in premenopausal women was not
significantly correlated with estrogen receptors.
Breast cancer in Indonesia showed a specific characteristic; it tends to be
found in a younger population than in other countries, with a median age
of 48 years compared to 68 years in European countries. Cancer at a
younger age is associated with a poorer prognosis and is more
progressive. A higher mitotic rate is poorly differentiated, tends to be
negative estrogen receptors, and is more likely to recur and metastasize.
The poor prognosis is further aggravated by the minimal awareness of
the Indonesian population for early detection. Thus, those who were
treated mostly were those with advanced stage.10
The differences in some studies' findings and different characteristics of
the Indonesian population have driven the study to run. If the
premenopausal estrogen hormone can affect the estrogen-receptor, then
the estrogen hormone can be manipulated to get a better prognosis.

The cross-sectional study proceeded in the Department of Surgery,
FMUI – CMGH enrolling patients treated from December 2021 to May
2022. The inclusion criteria were those who remain in premenopausal
age, i.e., stay to have menstruation regardless of age and patients who
underwent immunohistochemical examination of estrogen receptors.
Those who proceeded with hysterectomy, salpingo-oophorectomy, a
history of hormonal therapy, and chemotherapy were excluded. Those
who met the eligibility criteria were subjected to the study: some data
were recorded, i.e., history of menstrual periods and proceeded blood
estradiol test; the specimen was taken to the laboratory at CMGH. The
blood specimen is taken during the mid-cycle phase or ovulation phase
between the twelfth to the fourteenth day of each menstrual cycle. In the
study, estradiol is referred to as the variable of interest since estradiol is
the most active and predominant form of estrogen represents estrogen in
premenopausal breast cancer. Finally, the estrogen–receptor is obtained
through biopsy and/or surgical resection. The specimen was subjected
to immunohistochemical examination in the anatomical pathology
laboratory of CMGH. Data were subjected to statistical analysis to find
the correlation, and a p-value < 0.05 was considered statistically
significant. The committee of ethics, Faculty of Medicine, Universitas
Indonesia, approved the study.
The independent board reviewer, i.e., the Committee of Ethics, Faculty
of Medicine, Universitas Indonesia, approved the study (KET137/UN2.F1/ETIK/PPM.00.02/2022 and protocol number 22-010096).
Results
Thirty-two subjects met the eligibility criteria. The subject was 22–51
years and grouped by age according to the study by Kurnia et al., as
described in Table 1,11 and the value of estradiol and estrogen (in
median) as shown in Table 2.
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Table 1 Subjects characteristics
Characteristics
Age, n (%)
20–29
30–39
40–49
50

n = 32
3 (9.4)
8 (25)
17 (53.1)
4 (12.5)

Table 2. Estradiol and estrogen–receptor (n = 32)
Estradiol (pmol/L)
39.3 (15.3–89.8)
Estrogen receptor (%)
45 (10–90)

The following shows some research data with maximum and minimum
values of age, estradiol, and estrogen that may have clinical significance,
as seen in Table 3.
Table 3. Research data with a range of minimum and maximum values for age, estradiol
values, and estrogen receptor values
Subjects
1
2
3
4
5
6
7
8

Age (year)
22
28
28
39
42
50
50
51

Estradiol (pmol/L)
55.3
17.2
74.6
15.3
15.5
26.6
25.3
89.8

Estrogen–receptor (%)
20
10
45
70
50
30
90
50

The age distribution and estrogen–receptors data were not normal. Thus,
the Kruskal-Wallis test was used to analyze. The correlation between
age and estrogen receptors showed a p-value of 0.785. Mann-Whitney
test analysis was carried out to see the correlation of each group using
the 40-49 age group as a reference, and the results were as shown in
Table 4.
Table 4. Kruskal Wallis test between age and estrogen receptor
Age (year)

n

Estrogen receptor (%)

20–29
30–39
40–49
50

3
8
17
4

20 (10–45)
47.5 (10–70)
45 (10–80)
70 (30–90)

Overall pvalue
0.785*

p-value between
groups
0.631**
0.483**
Reference
0.417**

*

Kruskal Wallis test, **Mann Whitney test

With this distribution, the Spearman correlation test between estradiol
and estrogen receptors showed a p-value of 0.864 and a negative
correlation coefficient of 0.032.
Table 5 Spearman correlation test between estradiol and estrogen receptor
Spearman Correlation
Value of estradiol (pg/mL) Correlation coefficient
Sig (2-tail)
n

Estrogen receptor (%)
-0.032
0.864
32

Discussion
In this study, the 32 subjects enrolled are referred to as the minimum of
a calculated sample using a correlation coefficient of 0.5. The age of
subjects ranged from 22 to 51 years, with the highest frequency of 40–
49 years (n = 17, 53.1%). A previous study showed that the incidence of
breast cancer per 100,000 increases with age. For example, the incidence
of breast cancer in patients aged 20–24 years is 1.4 per 100,000, aged
25-29 years is about 8.1 per 100,000, aged 30–39 is about 58.4 per
100,000, and aged 40–49 is about 198.5. per 100,000. This can be
explained by hormonal factors, such as prolonged exposure to the
hormone estrogen will increase the risk of breast cancer.
The estradiol of 32 subjects in the study showed a normal value, with the
lowest of 15.3 pg/mL at the age of 39 years and the highest of 89.8
pg/mL at the age of 51. However, the data were not distributed normally,
with a median value of 39.3 pg/mL. This wide range remains normal,
considering that the reference value of estradiol in premenopausal
women in the mid-cycle phase is also wide, namely 38–649 pg/mL.

There is no categorical distribution for estradiol. Premenopausal
women's mid-cycle estradiol in research subjects was still in the normal
range. Theoretically, hormonal factors are risk factors for breast cancer.
The higher the endogenous estrogen hormone (estradiol), the higher the
risk of breast cancer. Estrogen would decrease at menopause, but it is no
data for a younger age, the higher the estrogen.17 There is also no pattern
of estradiol based on age. Estrogen receptors in these 32 subjects showed
a wide range between 10–90% with an abnormal distribution (median
45%). From this range, it was found that all subjects showed a positive
estrogen receptor type. Thus, the study is referred to as a study that
analyzed positive estrogen receptor subjects. Furthermore, in all
subjects, there is a tendency for lower estrogen receptorsat a younger
age; for example, the youngest subject, age 22 years, has a 20% estrogen
receptor, and at 28 years, it has a 20% estrogen receptor. Likewise, the
oldest subject was 51 years with a 50% estrogen receptor, and the 50year-old had a 90% estrogen receptor.
The correlation between age and estrogen receptors was then analyzed
to exclude this factor as a confounding factor. The analysis shows no
significant correlation (p = 0.785) both overall and between groups with
the age group 40–49 as a reference (with p values for each age group
20–29, 30–39, and 50, namely 0.631; 0.483; and 0.471, respectively).
Thus, it is concluded that age is not a confounding factor that may lead
to bias in the analysis of the correlation between estrogen and the
estrogen receptor. However, data showed that younger people tend to
have low estrogen receptor values. In addition, a previous study also
showed that breast cancer at a young age (premenopausal) is more
aggressive and tends to have negative estrogen receptors.10,18-21 Although
not statistically significant, we can conclude that there is a clinical
significance that the younger the age, the lower the estrogen receptor.
Therefore, surgeons can consider this to check estradiol in young breast
cancer patients to predict the treatment and prognosis of premenopausal
breast cancer patients. Hormonal factors include estrogen and
progesterone, while this study only focused on examining estradiol but
no other hormones. More prolonged hormone exposure increases the
risk of breast cancer. However, this study focused on the duration of
hormonal exposure of the subjects, such as the length of menstruation,
the first time of menstruation, history of pregnancy, and history of
breastfeeding.
The Spearman correlation test showed no statistically significant
correlation between estrogen and the estrogen receptor in
premenopausal breast cancer patients (p = 0.864). Although the
correlation coefficient has a minus value (r = -0.032), which means there
is an inverse correlation between the two variables. However, the
correlation is too weak that may be ignored. This can be caused by the
large range value of estradiol and estrogen receptors. The larger the
numerical range of the variables, the larger the subject is needed to obtain
significant and representative analysis findings. No reference explains
the correlation between estrogen levels and the estrogen receptor with
certainty. Theoretically, the higher the estrogen, the greater the risk of a
person may have breast cancer. The role of estrogen is to occupy the
estrogen receptor in breast cancer tissue, stimulating cell proliferation
and supporting cell mutations so that cancer is formed.22 Estradiol plays
a role in carcinogenesis by interacting with estrogen receptors, which
raises the question of whether the initial value of estradiol plays a role in
the estrogen receptor in breast cancer that causes cancer, especially at a
young age or premenopausal because it has more active and aggressive
cell dividing. From the theoretical explanation above, it can be
hypothesized that the higher the value of estrogen, the more aggressive
the cell proliferation in the breast, and the more progressive it will lead
to a worse prognosis, which was shown as the lower the value of the
estrogen-receptor. Thus, it can be said that estrogen and the estrogen
receptor have a negative correlation.
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The study findings showed no significant correlation between estrogen
and estrogen receptors in breast cancer patients at premenopausal age.
This is paralleled to the previous study.6,9 One large-scale case-control
study conducted in 10 European countries enrolling 801 breast cancer
cases showed no correlation between estradiol and progesterone on
estrogen receptors and the risk of breast cancer in premenopausal age.
The study found that the value of testosterone significantly correlated
with the estrogen receptor in postmenopausal-age patients.7 In this study,
the age of the study subjects was close to that of the subjects, with a
median age of 45.6 years (26.7–56.9). However, the number of research
subjects was much higher than in this study, and the characteristics of the
population in Europe were also different from Indonesia, with a more
heightened awareness of health examinations. In Indonesia, patients
tend to come with a long history of illness. Another study, a case-control
conducted in Malaysia with 207 breast cancer cases, examined the role
of estrogen, progesterone, testosterone, and prolactin in pre and
postmenopausal breast cancer patients. There were 73 cases of
premenopausal breast cancer analyzed in the study. The finding showed
that in the premenopausal group, there was no significant correlation
between hormones and the risk of breast cancer. However, in
postmenopausal age, estrogen and progesterone are risk factors with OR
1.48 – 4.23 and p values of 0.025 and 0.006. This study has a research
subject that is more similar to Indonesia because both are developing
countries in Southeast Asia.9

administration 123, resources 123, software 3, supervision 12, validation
12, visualization 3, writing – original draft preparation 3, writing –
review and editing 123.
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